4 to -20.2; P = 0.004). AV nodal effective refractory period was also impaired after dexmedetomidine and showed weak evidence for return to baseline function
after ketamine (mean difference between baseline and after ketamine -22.8 ms; 95% CI, -40.2 to -5.2; P = 0.069).
Conclusion: The concurrent use of ketamine may mitigate the negative chronotropic effects of dexmedetomidine.”
“A pyrochlore-like phase of composition Ho(2)MnRuO(7) has been synthesized by a soft-chemistry procedure followed by thermal treatments at moderate temperatures up to 900 degrees C for 12 h in air. It has been characterized by x-ray diffraction SCH727965 clinical trial and neutron powder diffraction (NPD), as well as dc and ac susceptibilities. As in the parent Ho(2)Mn(2)O(7) oxide, the magnetic Mn and Ru ions statistically occupy the 16c sites in a cubic unit cell with space group Fd (3) over barm, which define a potentially frustrated three-dimensional array of corner sharing (Mn, Ru)(4) tetrahedra. The dc and ac magnetic susceptibilities of Ho(2)MnRuO(7) display a sharp increase near 60 K. In addition, the field-cooled and zero-field-cooled curves diverge below 30 K. The ac data present frequency variability below 60 K and broad frequency dependent LOXO-101 manufacturer maxima at lower temperatures (similar to 30 K), suggesting a
spin-glass like behavior similar to Ho(2)Mn(2)O(7). However, a low-temperature NPD study of the magnetic structure unveils an antiferromagnetic coupling of two subsets of Mn(4+)/Ru(4+) selleckchem spins, indicating that the magnetic frustration is partially relieved by the random distribution of Mn and Ru over the 16c sites; at lower temperatures there is a polarization of the Ho(3+) magnetic moments, which also participate in the magnetic structure. Under an external magnetic field the Ho moments become totally polarized, giving a saturation magnetization at 2 K of 10.8 mu(B)/f.u. at 5 T. (C) 2010 American Institute of Physics. [doi:10.1063/1.3393994]“
“The aim of this study was to test the safety and efficacy of the Solyx single-incision sling (SIS) in women with stress
urinary incontinence (SUI).
A retrospective study of 63 women who had undergone implantation at three medical centers (December-March 2009) was conducted.
Mean patient age was 51 years (range, 30-87 years); 37 (59%) patients had concomitant urogynecological procedures. At a mean follow-up of 6.5 months (range, 5-8 months), 95% of patients were dry on the basis of subjective and objective assessment. Two patients experienced transient urinary retention, which resolved spontaneously. No complications of the procedure were reported, including no bladder, bowel, vessel, or nerve perforations and no erosions or extrusions. No pain was reported that was attributed to the implant.
The very early efficacy results indicate that the Solyx SIS system is an attractive treatment option for SUI. The minimal number of steps involved in the procedure will facilitate uptake of the technique.
No related posts.